Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026 /Actuate Therapeutics, ...